Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catheter Precision (VTAK) Research & Development (2017 - 2025)

Catheter Precision has reported Research & Development over the past 9 years, most recently at $328000.0 for Q4 2025.

  • Quarterly Research & Development rose 260.44% to $328000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $862000.0 through Dec 2025, up 216.91% year-over-year, with the annual reading at $862000.0 for FY2025, 216.91% up from the prior year.
  • Research & Development was $328000.0 for Q4 2025 at Catheter Precision, up from $276000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $3.7 million in Q4 2021 and troughed at -$11000.0 in Q4 2023.
  • The 5-year median for Research & Development is $197500.0 (2023), against an average of $1.0 million.
  • Year-over-year, Research & Development tumbled 107.14% in 2023 and then surged 927.27% in 2024.
  • A 5-year view of Research & Development shows it stood at $3.7 million in 2021, then tumbled by 95.87% to $154000.0 in 2022, then tumbled by 107.14% to -$11000.0 in 2023, then surged by 927.27% to $91000.0 in 2024, then surged by 260.44% to $328000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Research & Development are $328000.0 (Q4 2025), $276000.0 (Q3 2025), and $155000.0 (Q2 2025).